Macrophages and osteoclasts are thought to derive from CD68 lineage marker-positive common myeloid precursors. We used the CD68 promoter to drive an inducible receptor activator of NF-jB (iRANK) construct that selectively activates RANK signaling in myeloid cells in vivo. The cytoplasmic portion of RANK was fused to a mutant FK506 binding domain, which selectively binds the chemical inducer of dimerization AP20187 and initiates signaling. iRANK mRNA was expressed in macrophages isolated from peritoneal cavity, spleen-, and bone marrow-derived myeloid cells. Unexpectedly, AP20187 did not induce osteoclast formation in spleen-and bone marrowderived myeloid cells. However, AP20187-dependent RANK signaling induced ERK1/2 phosphorylation and mRNA expression of MMP9 and CathepsinK in peritoneal macrophages. Importantly, CD68 was not expressed until day 3 and day 5 in bone marrow and spleen myeloid cells, respectively. Contrary to dogma, osteoclast precursors do not express the lineage marker CD68.
Keywords: CD68; osteoclast precursors; RANK Macrophages and osteoclasts are thought to derive from a common myeloid progenitor, arising from hematopoietic stem cells in the bone marrow. Defined stimuli from the microenvironment induce commitment of the myeloid progenitor to a specific lineage [1] . The generation of the myeloid progenitors from hematopoietic stem cells is dependent on M-CSF and its receptor, CSF1R, and mice deficient in either factor lack both macrophages and osteoclasts [2] [3] [4] [5] . Receptor activator of NF-kB (RANK) is a membrane protein that binds RANK ligand (RANKL) and promotes signaling in both macrophages and osteoclast. In monocytes, RANKL/RANK signaling is also required for the generation of preosteoclasts from myeloid progenitors and further fusion and survival of mature, multinucleated osteoclasts [6, 7] . In contrast, osteoprotegerin (OPG) is a potent inhibitor of osteoclast differentiation and survival by binding RANKL and neutralizing its signaling through membrane RANK [8] [9] [10] . Together, M-CSF/CSF1R and the RANK/ RANKL/OPG axis act as the major regulators of osteoclast formation in the bone.
CD68, also known as macrosialin, is glycosylated type I transmembrane protein that belongs to the lysosome-associated membrane protein (LAMP) family [11] . Its expression is associated with the late endosome and lysosome organelles of cells of the myeloid lineage, which includes osteoclasts, microglia, and immature dendritic cells [12] . It has very little cell surface expression [13] . CD68 is commonly used as a histological marker due to its apparent monoycte/macrophage lineage specificity [2] . It has previously been used to direct transgene expression in both in vitro and in vivo model systems of gene therapy and its expression has been reported to be restricted to cells of the myeloid lineage, including osteoclast precursors [14] [15] [16] .
The goal of this study was to create a transgenic mouse conditionally expressing RANK in macrophage and osteoclast precursors. Therefore, we generated a transgenic mouse strain expressing a fusion protein comprising of the cytoplasmic domain of RANK linked to an inducible FK506-derived dimerization domain (iRANK) under the control of the human CD68 promoter (CD68trans-iRANK). The iRANK dimerization domain allows interaction with a chemical inducer of dimerization (CID) drug. As RANK requires trimerization for effective signaling, we have engineered two FK506-derived dimerization domains fused to the RANK cytoplasmic domain to ensure successful oligomerization [17] . Thus, in this system, the fusion protein (iRANK) is functionally inert unless directed to oligomerize by the addition of the CID, AP20187. We previously validated the same iRANK construct using a murine preosteoclastic cell line, RAW264.7. When treated with 50 nM of CID, iRANK-expressing RAW264.7 cells showed induction of tartrate-resistant acid phosphatase (TRAP) activity as well as formation of mineral resorbing multinucleated osteoclasts [17] . The current studies confirmed the expression and function of CD68-driven iRANK in macrophage precursors of transgenic mice, but no expression or function of this construct was observed in bone marrow-derived (BMD) or spleen-derived osteoclast precursors. Hence, our studies are the first to definitely show that osteoclast precursors do not express CD68 and that CD68-positive monocyte/ macrophages cannot give rise to osteoclasts.
Methods

Animals
All mice used in these studies were housed and bred in environmentally controlled rooms of an AALAC-accredited facility under 12-h light and dark cycles. They were fed ad libitum and were used in strict accordance with protocols preapproved by the Institutional Animal Care and Use Committee of University of Washington.
Generation of CD68trans-iRANK mice
All constructs were generated using standard molecular biology techniques and were confirmed by DNA sequencing. The c-Src myristylation domain (Myr), two copies of the F36v-modified FKBP12 domain (F2), and the RANK cytoplasmic domain (235-623 a.a.) were cut out of the pMGIFM-EGFP-IRES-Myr-F2-cRANK plasmid [17] using HindIII and NotI. The Myr-F2-cRANK portion was ligated into LZRS-CD68S-HA-EGFP vector downstream of CD68S [18, 19] . The vector was then digested with PvuII, ClaI, and SacII to remove excess backbone to obtain CD68S-Myr-F2-cRANK and gel purified using QIAquick Gel Extraction kit (Qiagen, Germantown, MD, USA) for pronuclear injections by University of Washington Preclinical Research and Transgenic Services.
Western blots
Whole cell lysates were collected using Laemmli buffer plus 19 Protease cocktail (Thermo Scientific, Waltham, MA, USA). Total protein was quantified using a BCA Protein assay kit (Promega #23235, Madison, WI, USA), and western blotting was performed using 10 or 30 lg proteinÁlane À1 on 12.5% SDS/PAGE reducing gels. Protein was transferred to 0.45 lm polyvinylidene difluoride (PVDF) and was subsequently blocked with 5% milk in Tris-buffered saline/0.05% Tween-20 (TBST) for 1 h before probing with primary antisera overnight at 4°C. Membranes were then washed 3 9 15 min with TBST, incubated with secondary antisera for 1 h, and then washed again. Blots were developed using Chemiluminescent Kit (Bio-Rad Laboratories #1705060, Berkeley, CA, USA) and the signal was captured with GeneMate Blue Autoradiography film (Bioexpress, Kaysville, UT, USA). The following antibodies and titers were used: anti-mouse CD68 (1 : 1000, Biolegend #137001, San Diego, CA, USA), rabbit polyclonal p44/42 MAPK (Erk1/2) (1 : 1000, Cell Signaling Technology #9102, Danvers, MA, USA), and rabbit polyclonal phosphor-p44/42 MAPK (1 : 1000, Cell Signaling Technology #4695). Donkey antirat (1 : 10 000, The Jackson Laboratory, West Grove, PA, USA) or donkey anti-rabbit (1 : 10 000, The Jackson Laboratory) horseradish peroxidase-conjugated secondaries were used to detect primary antibodies.
Cell culture
Mice (6-to 8-week old) were euthanized with CO 2 . Femurs and tibias were dissected from the mice, and remaining tissue was removed and bones were placed in 70% EtOH for 5 min before cutting off the ends. BMD cells were harvested for single cell suspensions by flushing femurs and tibias with 6 mL of RPMI 1640 (Life Technologies, Grand Island, NY, USA) media into 15 mL tubes using a 25 g needle. Cells were dispersed using an 18 g needle and spun down (270 g for 5 min). Supernatant was removed and cells were resuspended in 19 ACK (150 mM NH 4 Cl, 10 mM NaHCO 3 , 1 mM EDTA, pH 7.4) lysis buffer to remove red blood cells and incubated for 5 min. Cells were washed twice with 19 PBS. Cells were plated in 12-well plate at a density of 5 9 10 5 cellsÁwell À1 in a-MEM (Life Technologies, Carlsbad, CA, USA) media supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine, 100 UÁmL À1 penicillin, 100 lgÁmL À1 streptomycin, and 35% L929 condition media, a source of M-CSF. The cells were plated in three replicates in 12-well plates and incubated at 37°C with 5% CO 2 . Spleens were removed from 18-to 20-week-old mice and gently smashed through a 70 lm nylon strainer into 10 mL of RPMI 1640 medium using the plunger of a 6 mL syringe. Cells were then transferred to a 15 mL tube, spun down, supernatant removed, and the pellet lysed and washed similar to BMD cells. The pellet was resuspended in 19 PBS supplemented with 2% FBS and 1 mM EDTA and monocytes were isolated using an EasySep Mouse Monocyte Enrichment kit (StemCell Technologies, Vancouver, Canada #19761), according to the manufacturer's instructions. The cells were resuspended in a-MEM medium supplemented with 20% FBS, 2 mM L-glutamine, 100 UÁmL À1 penicillin, 100 lgÁmL À1 streptomycin, and 35% L929 condition media and plated in 12-well plate at a density of 5 9 10 5 cellsÁwell À1 .
For both BMD and spleen cultures, fresh medium was changed every 48 h and osteoclast formation was evaluated after 7 days in culture. Mice, 6-to 8-week old, were injected with 1 mL of 5% thioglycollate (BD Bioscience, Franklin Lakes, NJ, USA) 96 h prior to isolation. Mice were euthanized with CO 2 and the peritoneal membrane was separated from under the abdominal musculature. About 5 mL 19 PBS was injected into peritoneal cavity, the peritoneum was gently and completely massaged, and PBS was then aspirated from peritoneal cavity. Peritoneal cells were incubated with 19 
Results
To achieve expression of the iRANK protein in vivo in myeloid cells, we generated a construct (CD68trans-iRANK) that encodes, downstream of the human CD68 promoter, the iRANK fusion protein comprising the cytoplasmic domain of RANK linked to two FK506-derived dimerization domains (F36v; Fig. 1A ). CD68trans-iRANK transgenic mice were generated by pronuclear injection and genotyped to confirm iRANK transgene germline transmission. Genotyping primers spanned the CD68 promoter and the F36v domain. Two founder lines were generated from the pronuclear injections (Fig. 1B) . For each founder line, the mice were fertile and had no obvious developmental defects.
Expression of CD68trans-iRANK
To determine whether the CD68trans-iRANK construct was expressed in myeloid cells, we isolated bone marrow cells, spleen monocytes, and thioglycolate elicited peritoneal macrophages. Bone marrow cells and spleen cells were cultured in the presence of M-CSF up to 11 days, and peritoneal macrophages were cultured for 7 days. We first determined if iRANK mRNA was expressed in putative osteoclast precursor cells and macrophages by reverse transcription (RT)-PCR analysis. We verified that the iRANK construct was expressed in all cell types at various time points (Fig. 2) . Cells isolated from control nontransgenic mice, showed no mRNA expression of the iRANK construct. We compared iRANK mRNA expression with endogenous RANK expression (data not shown) and found endogenous RANK expression was present at every time point in both transgenic and nontransgenic mice. As the iRANK construct is strictly intracellular and FACS analysis surface expression detection would not be possible, we tried to use an antibody raised against the dimerization domain in an attempt to show expression of the iRANK protein.
However, despite our efforts we could not show expression of the iRANK protein by western blot.
CD68trans-iRANK does not induce osteoclastogenesis
We have previously shown that iRANK oligomerization with CID induced osteoclasts formation in transduced RAW264.7 cells [17] . As osteoclasts have been shown to form when BMD cells and spleen-derived monocytes were treated with RANKL [20, 21] , we asked whether treatment with the CID drug could induce osteoclast formation in the same cell types isolated from the CD68trans-iRANK mice. We cultured the BMD-and spleen-derived cells with either 50 nM or 100 nM CID for 7 days in the presence of M-CSF and then performed TRAP staining, a common assay used to assess multinuclear osteoclast formation. Treatment with 20 ngÁmL À1 RANKL was used as a positive control, and 0.05% ethanol (vehicle) as negative control as it is the CID resuspension solution. We found that CID could not induce osteoclast formation in either BMD or spleen-derived cells (Fig. 3B,E) . In contrast, RANKL was able to induce robust osteoclastogenesis in both cell types (Fig. 3C,  F) . We also noted very sparse TRAP-positive mononuclear cells in the cultures treated with CID and ethanol (Fig. 3A-D) for both genotypes, and this may be due to endogenous RANKL expression. Indeed, we have shown that BMD cells express very low levels of RANKL [22] .
CD68 is not expressed in early precursors
As we could not show expression of the iRANK protein, and most importantly osteoclasts could not be generated by CID treatment of cells isolated from CD68trans-iRANK mice, we determined the time line of CD68 expression in bone marrow-, spleen-, and peritoneal-derived cells. We used the same experimental condition as described above and whole cell lysates were . mRNA analysis for iRANK in bone marrow-derived cells, spleen-derived monocytes, and peritoneal macrophages. Monocytes/ macrophages were isolated from bone marrow (BMD) (A), spleen (B), and thioglycolate elicited from the peritoneal cavity (P. Macrophages) (C) of nontransgenic wild-type (WT) and CD68-iRANK transgenic mice (CD68-iRANK). Bone marrow-derived cells and spleen monocytes were cultured in the presence of M-CSF for up to 11 days. Peritoneal macrophages were cultured in media for up to 7 days. We used reverse transcription (RT)-PCR analysis to verify the iRANK construct expression in cell isolates at days 1, 3, 5, 7, 9, and 11 for bone marrow-derived cells and spleen-derived monocytes (A and B), and days 1, 3, 5, and 7 for peritoneal macrophages (C).
collected at various time points. We found that freshly isolated BMD and spleen-derived monocytes from both wild-type and CD68trans-iRANK mice did not express CD68 at early time points of cell isolation (Fig. 4A,B) . Indeed, CD68 was not detectable until day 3 and day 5 in BMD and spleen-derived monocytes, respectively (Fig. 4A) . In contrast, CD68 expression in peritoneal macrophages was strong at all time points (Fig. 4C ).
CD68trans-iRANK induces phospho-ERK1/2 and mRNA expression for MMP9 and CathepsinK
As freshly isolated peritoneal macrophages expressed CD68, we determined if iRANK was functional by analyzing phosphorylated-ERK induction. RANK/ RANKL pathway activates distinct signaling cascades, such as MAPK-ERK1/2. As ERK1/2 is downstream in the RANK/RANKL pathway, it can be used to assess whether iRANK is activated by CID treatment. We cultured peritoneal macrophages with CID for 5, 15, 30, and 60 min, collected whole cell lysates and determined phosphorylated ERK1/2 expression using western blots. Phospho-ERK1/2 was significantly upregulated in CD68trans-iRANK cells induced with 50 nM CID compared to EtOH, RANKL at 15 min.
In cells isolated from wild-type mice phospho-ERK1/2 was slightly induced by RANKL but not CID (Fig. 5) . Furthermore, we collected RNA from wild-type and CD68trans-iRANK peritoneal macrophages and performed RT-PCR expression studies for the RANK-induced proteases MMP9 and CathepsinK. Both protease mRNAs were elevated in response to RANKL treatment in wild-type and CD68trans-iRANK. However, MMP9 and CathepsinK mRNAs were induced by CID only in CD68trans-iRANK (Fig. 6 ).
Discussion
We have successfully generated and characterized a novel transgenic mouse expressing an inducible RANK construct under the control of the human CD68 promoter. These mice showed no obvious behavioral or gross phenotypic abnormalities. The current studies found that although iRANK transgene mRNA was detected by reverse transcriptase-PCR in bone marrow and spleen monocytes, in vitro osteoclastogenesis could not be induced by treatment with the CID drug. This is most likely due to late expression of CD68 protein at day 3 and 5, in bone marrow and spleen monocytes, respectively, and thus suggesting low activation of the CD68 promoter or inactivation of CD68 promoter-driven transcripts at early time points. In thioglycollateelicited peritoneal macrophages, iRANK mRNA was also expressed from the day of isolation and up to 7 days in culture. However, in contrast to BMD and spleen-derived cells, the CD68 protein was strongly expressed in these cells as soon as cells were cultured. Most importantly, peritoneal macrophages responded to the CID drug, as measured by induction of phosphorylated ERK1/2, a factor downstream of the iRANK and two established RANKL/RANK regulated proteases MMP9 and CathepsinK. Together these data indicate that CD68 is not expressed in osteoclast precursors arising from myeloid lineage cells and that osteoclast precursors become a separate lineage from the monocyte/dendritic precursors as early as day 1 postisolation of in vitro culturing.
Osteoclasts are multinucleated, bone-resorbing cells that are essential in bone remodeling and regulation of calcium homeostasis [23] . It has been shown that a multipotent myeloid progenitor derived from the hematopoietic stem cell gives rise to the megakaryocyte/erythroid lineage and the myeloid lineage [24] . At the transcriptional level, the transcription factor PU.1 is important in the differentiation and commitment of myeloid progenitors. PU.1 is implicated in the regulation of CSF1R, and ITGAM, which encodes for CD11b. Indeed, mice deficient in PU.1 die soon after birth, and show signs of osteopetrosis accompanied by lack of macrophages and osteoclasts [25] . The absence of both macrophages and osteoclasts suggests that PU.1 regulates the initial stage of myeloid differentiation. The Csf1 op/op , a mouse strain with a mutation in the M-CSF gene, and mice null for CSFR1 display osteopetrosis due to a reduction in circulating monocytes, macrophages, and osteoclasts [26] . These data suggest that M-CSF and CSFR1 are necessary for the Myeloid cells further differentiate into the granulocyte lineage (basophils, eosinophils, and neutrophils) and the monocyte lineage. Monocyte precursors differentiate into monocytes/macrophages, dendritic cells, and osteoclasts [7] . However, the phenotypic definition of the osteoclast precursors is remarkably varied. Osteoclast precursors were first defined as CD117 + (or c-Kit) CD115 + (or CSFR1) RANK À expressing cells, which were able to differentiate into osteoclasts and dendritic cells [28] . Further studies reported that additional markers identify these cells. The phenotype CD115 + Flt3 low CX3CR1 + Ly6C hi corresponds to macrophage/dendritic cell progenitors that can also differentiate into osteoclasts [1, [29] [30] [31] [32] . Thorough analysis of bone marrow, spleen, and peripheral blood monocytes determined that the progenitor population accounted for 0.1-0.3% of total nucleated cells in bone marrow [33] . In humans, flow cytometry analysis of cells isolated from human pediatric bone marrow found that osteoclast, macrophage, and dendritic precursors were restricted to CD11b low CD34 +
CD115
+ c-Kit + FLT3 + IL3Ra hi [34] . A similar study utilizing human peripheral blood also found that cells with osteoclastogenic potential were CD115 + CD34 + c-Kit + FLT3 + [35] . However, when these precursors appear during development and the precise temporal window for osteoclast precursor generation is unclear. Furthermore, it has been suggested that precursor immaturity enhances their ability to form mature osteoclasts [32] . We found that failure to express the iRANK engineered protein very early after isolation of bone marrow and spleen precursors resulted in the absence of CID-dependent induction of multinucleated and TRAP-positive osteoclasts even in the presence of M-CSF. Thus, our studies support the idea that early and possibly immature osteoclast precursors give rise to mature osteoclasts. While the RANKL/RANK system is essential to drive osteoclast development, differentiation, and survival from hematopoietic cells [36] , RANKL is not necessary for osteoclast precursor determination. These findings suggest that a timely expression of RANK on osteoclast precursors assures that a restricted number of precursors progress to mature cells. RANK expression is induced by M-CSF/CSFR1 [37] . Indeed, in our studies we found strong endogenous RANK mRNA expression in BMD and spleen-derived cells stimulated with M-CSF, which resulted in robust multinucleated TRAP-positive osteoclasts when stimulated with RANKL. However, we found weak expression of CD68 promoter-driven iRANK mRNA at day 1 and day 3 postisolation in bone marrow and spleen cells derived from the transgenic mice stimulated with M-CSF. These findings correlated with lack of expression of CD68 protein until day 3 and 5 in bone marrow and spleen, respectively, and no osteoclast formation when treated with CID. As CD68 protein detection was used as surrogate expression for iRANK, these findings suggest that the both iRANK and CD68 proteins were not expressed in myeloidderived osteoclasts precursors and were upregulated later in lineage differentiation. Indeed, fully differentiated peritoneal macrophages derived from the transgenic mice showed robust expression of CD68 and iRANK function. These results suggest that the window for osteoclast precursor determination is restricted to the early times after isolation and that continuous and prolonged stimulation of M-CSF shifts the cells to a macrophage/dendritic cell fate. Indeed, we have shown that after 7 days of culture in the presence of M-CSF BM-derived cells were not able to express TRAP protein in response to RANKL [22] . This result correlates well with the finding by Ashley et al. [38] showing that in vitro M-CSF increases expression of CD68 in BMD macrophages in a time-dependent manner.
In summary, we generated a novel transgenic mouse expressing an inducible RANK construct under the control of the human CD68 promoter. Our findings indicate that CD68 is not expressed in osteoclast precursors arising from myeloid lineage cells and that osteoclast precursors become a separate lineage from the monocyte/dendritic precursors as early as day 1 postisolation. These findings indicate that, contrary to dogma, CD68-positive hematopoietic cells are not osteoclast precursors.
